| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
|
N Engl J Med
|
2005
|
33.60
|
|
2
|
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
|
J Clin Oncol
|
2006
|
16.25
|
|
3
|
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.
|
N Engl J Med
|
2014
|
6.76
|
|
4
|
Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.
|
J Clin Oncol
|
2008
|
6.31
|
|
5
|
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.
|
N Engl J Med
|
2015
|
5.57
|
|
6
|
Adjuvant ovarian suppression in premenopausal breast cancer.
|
N Engl J Med
|
2014
|
5.18
|
|
7
|
Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer.
|
N Engl J Med
|
2010
|
5.17
|
|
8
|
Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
|
J Clin Oncol
|
2006
|
4.99
|
|
9
|
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.
|
Breast Cancer Res Treat
|
2008
|
4.84
|
|
10
|
Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.
|
J Clin Oncol
|
2011
|
4.81
|
|
11
|
Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
|
J Clin Oncol
|
2005
|
4.77
|
|
12
|
Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer.
|
J Clin Oncol
|
2012
|
4.57
|
|
13
|
Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27.
|
J Clin Oncol
|
2012
|
4.33
|
|
14
|
Bevacizumab added to neoadjuvant chemotherapy for breast cancer.
|
N Engl J Med
|
2012
|
4.10
|
|
15
|
Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer.
|
J Clin Oncol
|
2009
|
3.99
|
|
16
|
Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20.
|
J Clin Oncol
|
2010
|
3.79
|
|
17
|
Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials.
|
J Clin Oncol
|
2006
|
2.83
|
|
18
|
Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial.
|
Lancet Oncol
|
2012
|
2.65
|
|
19
|
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
|
Lancet Oncol
|
2013
|
2.59
|
|
20
|
Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial.
|
J Clin Oncol
|
2008
|
2.55
|
|
21
|
Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24.
|
J Clin Oncol
|
2012
|
2.34
|
|
22
|
Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.
|
J Natl Cancer Inst
|
2013
|
2.28
|
|
23
|
Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.
|
J Clin Oncol
|
2013
|
2.12
|
|
24
|
Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20.
|
Breast Cancer Res Treat
|
2011
|
2.08
|
|
25
|
Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial.
|
Oncologist
|
2010
|
1.64
|
|
26
|
HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
|
Clin Cancer Res
|
2008
|
1.63
|
|
27
|
Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial.
|
J Clin Oncol
|
2011
|
1.56
|
|
28
|
Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer.
|
J Clin Oncol
|
2011
|
1.32
|
|
29
|
A randomized clinical trial of adjuvant chemotherapy for radically resected locoregional relapse of breast cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37.
|
Clin Breast Cancer
|
2008
|
1.04
|
|
30
|
Pathological complete response in neoadjuvant treatment of breast cancer.
|
Ann Surg Oncol
|
2015
|
1.03
|
|
31
|
A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer.
|
Clin Breast Cancer
|
2010
|
1.00
|
|
32
|
Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment.
|
Breast Cancer Res Treat
|
2009
|
0.93
|
|
33
|
A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.
|
Eur J Cancer
|
2013
|
0.92
|
|
34
|
The emerging role of lapatinib in HER2-positive breast cancer.
|
Curr Oncol Rep
|
2008
|
0.87
|
|
35
|
Pemetrexed/oxaliplatin for first-line treatment of patients with advanced colorectal cancer: a phase II trial of the National Surgical Adjuvant Breast and Bowel Project Foundation Research Program.
|
Clin Colorectal Cancer
|
2005
|
0.87
|
|
36
|
Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.
|
Clin Breast Cancer
|
2011
|
0.83
|
|
37
|
A phase II clinical trial of ZD1839 (Iressa) in combination with docetaxel as first-line treatment in patients with advanced breast cancer.
|
Invest New Drugs
|
2007
|
0.83
|
|
38
|
Anthracyclines in the treatment of HER2-negative breast cancer.
|
J Natl Cancer Inst
|
2007
|
0.81
|
|
39
|
Overcoming treatment challenges in advanced breast cancer.
|
Semin Oncol Nurs
|
2007
|
0.78
|
|
40
|
Drug development: neoadjuvant opportunities in breast cancer.
|
Am Soc Clin Oncol Educ Book
|
2013
|
0.76
|
|
41
|
A Phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies.
|
Clin Cancer Res
|
2003
|
0.76
|
|
42
|
Trastuzumab for early breast cancer.
|
Lancet
|
2006
|
0.75
|
|
43
|
Reply to E.J. Moylan et al.
|
J Clin Oncol
|
2014
|
0.75
|
|
44
|
The half century of clinical trials of the National Surgical Adjuvant Breast And Bowel Project.
|
Semin Oncol
|
2008
|
0.75
|
|
45
|
Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer.
|
Womens Health (Lond Engl)
|
2009
|
0.75
|
|
46
|
Rationale and clinical trial design for evaluating gemcitabine as neoadjuvant and adjuvant therapy for breast cancer.
|
Clin Breast Cancer
|
2004
|
0.75
|
|
47
|
Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies.
|
Cancer Chemother Pharmacol
|
2009
|
0.75
|
|
48
|
Gemcitabine/epirubicin/paclitaxel as neoadjuvant chemotherapy in locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.
|
Clin Breast Cancer
|
2008
|
0.75
|